Sign Up to like & get
recommendations!
0
Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0161-5
Abstract: Data from a phase II trial involving patients with relapsed glioblastoma following chemoradiotherapy, a setting in which few evidence-based therapies are currently available, demonstrate the superiority of the anti-angiogenic tyrosine-kinase inhibitor regorafenib over lomustine chemotherapy.…
read more here.
Keywords:
glioblastomas respond;
relapsed glioblastomas;
oncology;
regorafenib ... See more keywords